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Abstract Werner Syndrome (WS) is a human seg-
mental progeria resulting from mutations in a DNA
helicase. WS fibroblasts have a shortened replicative
capacity, an aged appearance, and activated p38
MAPK, features that can be modulated by inhibition
of the p38 pathway. Loss of the WRNp RecQ helicase
has been shown to result in replicative stress,
suggesting that a link between faulty DNA repair
and stress-induced premature cellular senescence may
lead to premature ageing in WS. Other progeroid
syndromes that share overlapping pathophysiological
features with WS also show defects in DNA process-
ing, raising the possibility that faulty DNA repair,
leading to replicative stress and premature cellular
senescence, might be a more widespread feature of
premature ageing syndromes. We therefore analysed
replicative capacity, cellular morphology and p38
activation, and the effects of p38 inhibition, in
fibroblasts from a range of progeroid syndromes. In
general, populations of young fibroblasts from non-
WS progeroid syndromes do not have a high level of
cells with an enlarged morphology and F-actin stress
fibres, unlike young WS cells, although this varies
between strains. p38 activation and phosphorylated
HSP27 levels generally correlate well with cellular
morphology, and treatment with the p38 inhibitor
SB203580 effects cellular morphology only in strains
with enlarged cells and phosphorylated HSP27. For
some syndromes fibroblast replicative capacity was
within the normal range, whereas for others it was
significantly shorter (e.g. HGPS and DKC). However,
although in most cases SB203580 extended replicative
capacity, with the exception of WS and DKC the
magnitude of the effect was not significantly different
from normal dermal fibroblasts. This suggests that
stress-induced premature cellular senescence via p38
activation is restricted to a small subset of progeroid
syndromes.
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Introduction
Much remains to be discovered regarding the patho-
physiology of human senescence (Puzianowska-
Kuznicka and Kuznicki 2005), a complex process
involving genetic and environmental factors affecting
several physiological pathways. One mechanism
commonly postulated as underlying human ageing is
replicative cellular senescence, or the observation that
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many normal human somatic cells are capable of only
a finite number of divisions (Campisi 1996; Ostler
et al. 2002; Burton 2009; Faragher et al. 2009).
Replicative senescence in fibroblasts results from the
progressive loss of telomeric repeats at the ends of
chromosomes due to the inability of the DNA
replication machinery to efficiently duplicate the 50
ends of linear chromosomes (Harley et al. 1990; Hastie
et al. 1990; Blackburn 1991; Allsopp et al. 1992;
Vaziri et al. 1994). Telomeres shorten with each cell
generation until a critical length is reached whereupon
they lose their function, resulting in a signal to exit the
cell cycle (d’Adda di Fagagna et al. 2003).
Replicative senescence can contribute to age-
related degenerations in division competent tissues
as a result of reduced proliferative capacity in organs
where cell division is central to normal function or
repair (e.g. small intestine, immune system, skin), or
from the observation that senescent cells display
deleterious biochemical features as a result of patterns
of gene expression that differ markedly from their
dividing counterparts (Ostler et al. 2002; Kipling et al.
2004; Burton 2009; Faragher et al. 2009). For
example, senescent cells secrete inflammatory cyto-
kines such as IL-1 and tumour necrosis factor (TNFa)
(Kumar et al. 1993; Parrinello et al. 2005), and express
cell surface molecules such as ICAM-1 that are
involved in the recruitment of leukocytes during
inflammation (Gorgoulis et al. 2005).
Evidence for replicative senescence in vivo has
been difficult to acquire, and a possible relationship
between the replicative capacity of fibroblasts in vitro
and human age has been found lacking in a re-
evaluation (Cristofalo et al. 1998), leading to criticism
of this postulate (Rubin 2002). However, several
observations suggest that senescent cells do occur
in vivo and accumulate with age (Lindsey et al. 1991;
Vaziri et al. 1994; Chang and Harley 1995; Dimri et al.
1995; Paradis et al. 2001; Vasile et al. 2001; Minamino
et al. 2002; Herbig et al. 2006; Jeyapalan et al. 2007),
and modulations that lengthen life span, such as
dietary restriction in mice, reduce the rate of accumu-
lation of senescent cells in the eye (Li et al. 1997).
Various practical difficulties underlie human age-
ing studies, most importantly the polygenic nature of
many of the associated pathologies. An alternative to
the study of whole body ageing in normal humans is
the study of progeroid syndromes whose phenotypes
show specific characteristics of ageing (Hofer et al.
2005; Kudlow et al. 2007). Most progeroid syndromes
where the aetiological factors are known are mono-
genic and segmental, in that they show many, but not
all, of the clinical characteristics of normal ageing. In
those aspects where premature ageing occurs, the
process and pathology are remarkably similar to that
seen in normally aged individuals (Hofer et al. 2005;
Kudlow et al. 2007).
One of the more intensively studied progeroid
syndromes is Werner (WS), with affected individuals
showing premature onset of cataracts, skin atrophy,
hair-greying and soft tissue calcification, together with
age-related diseases such as type II diabetes, athero-
sclerosis and osteoporosis (Martin et al. 1999).
Associated with the premature skin ageing, acceler-
ated cellular replicative senescence is found in WS
fibroblasts (Tollefsbol and Cohen 1984). This accel-
erated senescence of WS cells in vitro has been
postulated to correspond to a similar process in vivo,
and thus contribute to the accelerated ageing of
division-competent tissues (Ostler et al. 2002).
Likewise, many strains of Hutchinson-Gilford
Progeria (HGPS) fibroblasts show reduced replicative
capacity, although increased apoptosis is also pre-
valent, and HGPS individuals undergo rapid ageing
and have very short lifespans (Brown 1992; Hofer
et al. 2005). With Ataxia-telangiectasia (AT), the
replicative capacity of fibroblasts is significantly
reduced compared to normal (Elmore and Swift
1976; Tchirkov and Lansdorp 2003). Individuals with
AT show moderate features reminiscent of premature
ageing, such as grey hair, wrinkled skin, skin atrophy
and sclerosis, and show a reduced lifespan with death
usually occurring in the third and fourth decades
(Taylor et al. 1996).
In addition to replicative senescence, human fibro-
blasts can undergo stress-induced premature senes-
cence (SIPS) via activation of the MAP kinase p38 that
responds to and is activated by endogenous and
exogenous cellular stress (Freund et al. 2011). p38 is
involved in growth arrest in response to the expression
of oncogenes such as ras (Wang et al. 2002; Deng et al.
2004), exogenous stress such as arsenite treatment or
oxidative stress (Guay et al. 1997) and in telomere-
dependent senescence (Iwasa et al. 2003): indeed, p38
defines a common senescence signalling pathway
(Iwasa et al. 2003). p38 is important for senescence
growth arrest due to its ability to activate both the p53/
p21WAF1 and pRb/p16INK4A growth arrest pathways.
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Recent work using young WS fibroblasts has shown
that both the cellular replicative capacity and aged
morphology of WS fibroblasts can be reverted to that
seen for normal fibroblasts by treatment with the p38
inhibitor SB203580 (Davis et al. 2005; Davis et al.
2006). This, together with the observation of active
p38 stress signalling, suggests that a form of SIPS
is active in WS cells. As replicative senescence in WS
cells is telomere dependent (Davis et al. 2003), this
suggests that SIPS acts in synergy with telomere-
shortening to result in the premature cellular repli-
cative capacity (Davis and Kipling 2006). WS is
associated with inflammatory conditions, such as
atherosclerosis, diabetes and osteoporosis (Murano
et al. 1997; Choi et al. 2001; Yokote et al. 2004; Davis
and Kipling 2006). Because p38 activation leads to
the production of pro-inflammatory cytokines such as
IL-1 and TNFa (Ferran et al. 1995), it is possible that
elevated p38 activity in vivo in WS individuals may
lead to the observed elevated levels of p38-inducible
inflammatory cytokines, and thus plays a role in WS
pathophysiology (Davis and Kipling 2006).
In contrast, although AT fibroblasts have a shorter
replicative capacity than normal fibroblasts, they do
not show an aged-morphology or have activated p38,
and inhibition of p38 does not extend their replicative
capacity beyond that seen in normal fibroblasts (Davis
and Kipling 2009). In addition, AT individuals do not
show inflammatory features (Wood et al. 2001;
Barzilai et al. 2002; Hofer et al. 2005). This suggests
that SIPS is not a feature of AT, and that the shortened
replicative capacity of AT fibroblasts results from a
different process, such as accelerated telomere short-
ening (Tchirkov and Lansdorp 2003).
Based upon these studies it has been suggested
that premature cellular senescence and p38 activation
may underlie many of the premature ageing features of
other of these progeroid syndromes (Davis and
Kipling 2006). To address this question requires a
greater understanding of the replicative capacity and
p38 stress-signalling pathway in these syndromes. We
therefore sought to determine whether the lesions
present in these syndromes result in p38 activation and
a phenotype similar to SIPS as a result of endogenous
physiological levels of stress (which is distinct from
their ability to respond to exogenously applied stress),
and thus whether a SIPS-like response is a common
response in progeroid syndromes. We have therefore
determined the growth characteristics and replicative
capability of fibroblasts from several progeroid syn-
dromes and investigated the role played by p38 MAP
kinase, using a combination of molecular profiling and
small molecule inhibitor use. Furthermore, because
telomere shortening is known to synergise with SIPS
in WS fibroblasts and is a major mechanism driving
fibroblast senescence, we have also used ectopic
expression of human telomerase to determine whether
replicative senescence in fibroblasts from progeroid
syndromes is telomere-dependent.
Materials and methods
Cell culture
Primary dermal fibroblasts for the majority of the
syndromes used in this work were derived from
biopsies of human tissue and obtained from the Coriell
Cell Repository (Camden, NJ, USA). The two NBS
strains RO202 and RO242 were obtained from W.J.
Kleijer. For clarity, when referring to cell strains
each strain code is represented by an abbreviated
syndrome prefix with the strain code in brackets, e.g.,
SS(GM09812) for Seckel Syndrome cells (see Sup-
plementary Table 1). Normal dermal fibroblasts
(NDFs) are given the prefix N. HCA2tert cells have
been described previously (Davis and Kipling 2009).
The genetic lesions found in the cell strains used in this
study are shown in supplementary Table 2, as far as
they are known.
All cells were grown in Earle’s modified Eagle
medium (EMEM: Gibco Invitrogen, Paisley, UK)
supplemented with 10 % foetal calf serum (Autogen
Bioclear, Salisbury, UK), 19 vitamins, 2 mM L-glu-
tamine (Invitrogen Life Technologies Ltd., Paisley,
UK), 19 essential amino acids, 19 non-essential
amino acids, 1 mM sodium pyruvate, 10,000 U/ml
penicillin and 10 mg/ml streptomycin (Sigma, Poole,
UK) in an atmosphere of 21 % O2 and 5 % CO2,
and passaged every 4–5 days as described previously
(Davis et al. 2003). Cultures were not allowed to
become confluent at any time so as to maintain
maximal growth rates. Population doublings (PDs)
were calculated according to the formula: PDs =
log(Nt/No)/log2, where Nt is number of cells counted
and No is number of cells seeded. The initial growth
rates for all cultures were determined using the first
30 days of culture when the growth was still on
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the linear part of the growth curve. An example growth
curve for each progeroid syndrome is shown in
Supplementary Figure 1.
For experiments using p38 MAP kinase inhibitors,
the medium was supplemented with 2.5 lM
SB203580 (Tocris Chemical Co. Bristol, UK) dis-
solved in DMSO, with the medium changed daily. For
controls, an equivalent volume of DMSO was added to
the medium. 2.5 lM was chosen because this con-
centration is in the range used routinely for studying its
effect on p38 activity in cellular systems (Haq et al.
2002; Wang et al. 2002; Iwasa et al. 2003; Davis et al.
2005). We have previously shown that this concen-
tration effectively inhibits p38 while not significantly
inhibiting the related JNK1/2 kinases (Bagley et al.
2010).
To activate the p38-signalling pathway using
anisomycin, N(AG16409)tert or HCA2tert cells were
plated onto 100 mm dishes in EMEM and cultured for
2 days at 37 C, after which the cells were treated with
30 lM anisomycin (Sigma, Poole, UK) for 45 min.
Immunofluorescence microscopy
Actin staining for immunofluorescence microscopy
was performed essentially as described (Huot et al.
1997). Briefly, the cells were plated into 35 mm
plastic dishes in EMEM and allowed to settle for 48 h.
The cells were then washed in PBS, fixed in 3.7 %
(w/v) paraformaldehyde for 20 min and permeabilised
with 0.1 % (v/v) Triton-X100 for 20 min. F-actin was
detected using fluorescein isothiocyanate-conjugated
(FITC)-conjugated phalloidin (33 lg/ml) (Sigma,
Poole, UK), diluted 1:50 in PBS for 30 min in the
dark, followed by washing in PBS.
Immunoblot analysis
Protein samples were prepared in lysis buffer contain-
ing the phosphatase inhibitors NaF and Na3VO4,
separated on 12 % (w/v) sodium-dodecylsulphate/
polyacrylamide electrophoresis gels, electroblotted to
Immobilon-P polyvinylidene difluoride or nitrocellu-
lose membranes (Millipore, Watford, UK) and anti-
bodies applied as described previously (Davis et al.
2005). The antibodies used were: mouse monoclonal
anti-HSP27 (G31), rabbit polyclonal anti-phos-
pho(S82)-HSP27, anti-p38 and anti-phospho(T180/
Y182)-p38 (Cell Signalling, New England Biolabs,
Hitchin, UK). An enhanced chemiluminescence kit
(GE Healthcare, Chalfont St Giles, UK) was used for
visualization using HRP-coupled goat secondary
antibodies.
Retroviral gene transfer
pBABE-hTERT is an amphotropic retrovirus express-
ing the catalytic protein subunit of human telomerase
hTERT (Wyllie et al. 2000). For control infections
pBABE-puro vectors packaged in wCRIP cells were
used. Gene transfer was carried out as described
previously (Davis et al. 2003). 100,000 cells were
plated onto 100 mm culture dishes in EMEM and left
to settle for 48 h at 37 C, after which time polybrene
was added to a final concentration of 8 lg/ml for 1 h.
The medium was then replaced with 5 ml of viral
supernatant in growth medium (either pBABE-
hTERT-puro or pBABE-puro at approximately 1 9
105 viral particles per ml) and the cells incubated at
37 C for 24 h. For each gene transfer the retroviral
infections were performed twice. 24 h after the second
infection, fibroblast cultures were passaged into
EMEM containing puromycin at 2.5 lg/ml and sur-
viving cells after 5 days were transferred to T75
culture vessels and cultured in EMEM containing
puromycin and grown until they had surpassed at least
twice the replicative capacity of the uninfected
controls. Cell strains expressing telomerase activity
are given the suffix ‘tert’.
Detection of telomerase activity
Telomerase was assayed in whole cell extracts using
the TRAP assay as described (Kim and Wu 1997). The
cell line 293 provided a telomerase-positive control.
Reaction products were separated on non-denaturing
10 % polyacrylamide gels and visualized by Sybr Gold
staining and fluorimaging on a STORM phosphorim-
ager using blue fluorescence mode (AP Biotech).
Results
Effects of the p38 MAPK inhibitor SB203580
on the growth of normal human fibroblasts
In our previous work (Davis and Kipling 2009) we
grew dermal fibroblasts (NDF) from four normal
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individuals in the presence or absence of SB203580
until each strain reached replicative senescence, and in
this current study we analysed a further four NDF
strains (data summarised in Table 1). NDFs derived
from these eight individuals had an average replicative
capacity of 38.8 ± 10.5 PDs. This was extended to
46.6 ± 12.1 PDs in the presence of SB202580. This
increase in experimental replicative capacity for these
normal strains is 29.7 ± 11.6 % (Table 1; Fig. 1).
This compares to a replicative capacity extension
seen in WS and AT fibroblasts of 158.7 ± 61 %
(p \ 0.00016) and 43.8 ± 16.8 % (p [ 0.14) respec-
tively (see Fig. 1). The eight strains of NDFs had
average initial growth rates of 0.29 ± 0.09 PDs/day,
and SB203580 treatment increased the initial growth
rate to an average of 0.40 ± 0.13 PDs/day (Table 1).
Effects of SB203580 on the growth of fibroblasts
from genomic instability and progeroid syndromes
Fibroblasts from eight different genomic instability
and progeroid syndromes (CSA/CSB, BS, RTS,
HGPS, SS, DKC and NBS) were grown to replicative
senescence in the presence or absence of SB203580
and their replicative capacities and growth rates
recorded. These were compared to previous data for
WS and AT (all growth data are summarised in
Table 1). An illustrative growth curve for each of the
eight syndromes in used this work syndrome is shown
in Supplementary Figure 1.
Bloom syndrome (BS) cells had an average repli-
cative capacity (22.5 ± 2.8 PDs, and 32.8 ± 3.2 PDs
in the presence of SB203580, n = 3 strains) that is not
significantly different to NDFs (Table 1). In addition,
the average experimental replicative capacity exten-
sion with SB203580 treatment and their growth rates
were not significantly higher than seen for NDFs
(Table 1; Fig. 1).
A single strain of Cockayne Syndrome A (CSA)
cells was analysed. CSA(GM01856) cells achieved a
replicative capacity of 21.1 PDs that was extended to
29.9 PDs with SB203580 treatment (Table 1). The
growth rate also increased from 0.37 to 0.49 PDs/day
(Table 1). Although the replicative capacity for con-
trol-treated CSA cells was significantly shorter than
for normal cells (p \ 0.045; z-test), it should be noted
these cells had already been passaged seven times
before analysis. The growth rates and experimental
increase in replicative capacity with SB203580 were
not statistically significant from NDFs (Table 1;
Fig. 1).
Two strains of Cockayne Syndrome B (CSB) cells
were analysed. Each had an average replicative
capacity not significantly different from that seen in
normal cells (Table 1). The replicative capacity of
CSB cells in the presence of SB203580, however, was
significantly greater than seen in SB203580-treated
NDFs (p \ 0.02; Table 1), although the replicative
capacity extension was not (Fig. 1). The growth rates
of both strains in the presence or absence of SB20
3580 was significantly greater than seen for NDFs
(Table 1).
Three strains of Hutchinson-Gilford Progeria Syn-
drome (HGPS) cells were analysed. Their average
replicative capacity was 14.3 ± 10.5 PDs, which is
significantly shorter than seen for NDFs (p \ 0.008).
Average replicative capacity in the presence of
SB202580 (19.5 ± 13.3 PDs) was also significantly
reduced compared to SB203580-treated normal cells
(p \ 0.011). The percentage increase in replicative
capacity was statistically different from that seen in
NDFs at 46.1 ± 2.1 % (p \ 0.043; Fig. 1).
A single strain of Seckel Syndrome (SS) cells,
SS(GM09812), was analysed. It does not have a
mutation in ATR (Alderton et al. 2004), and its
aetiology is unknown. This strain had a replicative
capacity in the presence or absence of SB203580 that
was within the normal range (Table 1). The growth
rate of SS(GM09812) cells, however, was statistically
higher than that seen for NDFs.
Two strains of Nijmegen Breakage Syndrome
(NBS) cells were studied. Both were diagnosed by
clinical means (Der Kaloustian et al. 1996; Yamazaki
et al. 1998) and no mutation data are available. Both
strains had replicative capacities and growth rates not
statistically different to that of NDFs (Table 1).
A single Rothmund Thomson (RTS) strain was
studied. This had growth parameters within the range
seen for NDFs, with the exception of the replicative
capacity extension seen with SB203580, which was
higher (Table 1). However, when the current data is
added to previous results (Davis et al. 2012) fibroblasts
from RTS had growth parameters not significantly
different from NDFs (Table 1; Fig. 1).
Two strains of X-linked Dyskeratosis congenita
syndrome cells were used, one of which [DKC
(AG04645)] failed to proliferate sufficiently to allow
growth data to be obtained. The remaining strain
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Table 1 Replicative capacity and growth rates of fibroblasts grown in presence or absence of SB203580
Strain PDs achieved
(control)a
PDs achieved
(SB203580)a
% increase in replicative
capacityb
Growth rate
(control)c
Growth rate
(SB203580)c
N(AG04552) 24.3 30.1 40.6 0.17 0.24
N(AG06234) 34.1 41.6 39.3 0.26 0.40
N(AG09603) 47.8 55.7 24.8 0.33 0.40
N(AG11020) 41.7 46.5 14.7 0.39 0.45
N(AG11081) 33.4 39.3 28.9 0.33 0.41
N(AG13152) 28.0 35.6 34.5 0.15 0.19
N(AG13156) 46.6 63.4 42.4 0.36 0.55
N(AG16409) 54.3 60.5 12.3 0.39 0.55
Mean 38.8 ± 10.5 46.6 ± 12.1 29.7 ± 11.6 0.29 ± 0.09 0.4 ± 0.13
BS(GM02520) 19.3 29.3 51.8 0.18 0.40
BS(GM02548) 23.8 35.5 49.1 0.37 0.48
BS(GM02932) 24.5 33.7 37.5 0.32 0.43
Mean 22.5 ± 2.8 32.8 ± 3.2 46.1 ± 7.6 0.29 ± 0.1 0.44 ± 0.04
Probabilityd p [ 0.063 p [ 0.09 p [ 0.052 p [ 0.91 p [ 0.64
CSA(GM01856) 21.1 29.9 41.7 0.37 0.49
Probabilitye p \ 0.045 p [ 0.095 p [ 0.13 p [ 0.22 p [ 0.23
CSB(GM10903) 51.4 67.2 30.7 0.54 0.67
CSB(GM10905) 61.2 79.2 29.4 0.64 0.76
Mean 56.3 ± 6.9 73.2 ± 8.5 30.0 ± 0.9 0.59 ± 0.07 0.71 ± 0.06
Probabilityd p [ 0.059 p \ 0.02 p [ 0.96 p \ 0.004 p \ 0.012
HGPS(AG01972) 14.4 20.9 45.1 0.29 0.40
HGPS(AG10677) 3.8 5.5 44.7 0.13 0.17
HGPS(AG11498) 24.8 32.0 48.6 0.38 0.39
Mean 14.3 ± 10.5 19.5 ± 13.3 46.1 ± 2.1 0.27 ± 0.13 0.32 ± 0.13
Probabilityd p \ 0.008 p \ 0.011 p \ 0.043 p [ 0.67 p [ 0.39
SS(GM09812) 32.9 39.1 18.8 0.50 0.62
Probabilitye p [ 0.28 p [ 0.27 p [ 0.17 p \ 0.016 p \ 0.044
NBS(RO202) 43.1 48.8 13.2 0.34 0.38
NBS(RO242) 53.5 26.9 67.9 0.35 0.41
Mean 48.3 ± 7.3 58.4 ± 13.5 20.0 ± 9.7 0.345 ± 0.007 0.39 ± 0.02
Probabilityd p [ 0.26 p [ 0.26 p [ 0.31 p [ 0.51 p [ 0.96
DKC(GM01774) 11.9 16.5 78.0 0.15 0.22
Probabilitye p \ 0.006 p \ 0.007 p \ 0.003 p [ 0.076 p [ 0.086
RTS cells:
RTS(AG05013) 45.4 58.9 55.5 0.38 0.55
Meanf 30.5 ± 15.3 39.6 ± 18.5 37.5 ± 21.8 0.33 ± 0.07 0.5 ± 0.14
Probabilityd p [ 0.51 p [ 0.44 p [ 0.24 p [ 0.59 p [ 0.22
AT cellsg
Mean 19.6 ± 7.2 25 ± 8.02 43.9 ± 16.8 0.24 ± 0.11 0.33 ± 0.06
Probabilityd p \ 0.018 p \ 0.021 p [ 0.14 p [ 0.26 p [ 0.43
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[DKC(GM01774)] managed 11.9 PDs that was
extended to 16.5 PDs using SB203580 (Table 1), an
experimental replicative capacity extension of 78 %
taking into account the six PDs achieved prior to
obtaining the cells. Its replicative capacity was
significantly less than NDFs and showed a statistically
significantly greater replicative capacity extension
following SB203580 treatment (Table 1; Fig. 1). Its
growth rate, although slightly below the range for
normal cells, was not significantly different from
normal NDFs using a z-test.
Comparison of cellular morphologies of normal
and progeroid syndrome cells
A striking feature of young WS cells in culture is that
the majority have an enlarged morphology and an
extensive network of F-actin stress fibres (Davis et al.
2005) that can be visualised with phalloidin-FITC
(Fig. 2a). Treatment of WS cells with SB203580
restores a normal morphology (Fig. 2b: compare with
Fig. 2c). In contrast, cultures of normal fibroblasts
show very few (\5 %) cells with extensive F-actin
stress fibres (Fig. 2c), with the majority having a
normal morphology (Davis and Kipling 2009). The
progeroid and genomic instability syndromes used in
this study can be divided into three distinct groups
with respect to the cellular morphology of fibroblasts
and its response to SB203580 treatment (Table 2).
Group 1 syndromes are those where the fibroblast
morphology differs little from NDFs. The cultures
having a few enlarged cells with F-actin stress fibres,
but the majority having a normal morphology; these
cultures are not affected by SB203580 treatment. This
pattern is seen for both NBS strains, RTS(GM05013),
and SS(GM09812) (Fig. 2d–f), and is similar to what
has been reported previously in Ataxia-telangiectasia
cells (Davis and Kipling 2009).
Group 2 syndromes are those that show inter-strain
differences in fibroblast morphology and include the
BS, HGPS, CSA and CSB strains. CSA(GM01856)
cultures have up to 20 % cells with an enlarged
Fig. 1 Bar chart showing mean percentage increase in
experimental replicative capacity using SB203580 for each
syndrome; the probability that the increase seen is within the
range for normal cells is given for those that are statistically
significant
Table 1 continued
Strain PDs achieved
(control)a
PDs achieved
(SB203580)a
% increase in replicative
capacityb
Growth rate
(control)c
Growth rate
(SB203580)c
WS cellsh
Mean 19.9 ± 4.4 36.5 ± 10.6 158.7 ± 61.5 0.11 ± 0.04 0.28 ± 0.09
Probabilityd p \ 0.017 p [ 0.24 p \ 0.00016 p \ 0.011 p [ 0.17
a Total PDs achieved including any known PDs cells have already done prior to obtaining them from Coriell Repository
(Supplementary Table 1)
b The % increase is determined with reference to starting PD as far as possible: e.g., for N(AG04552) the replicative capacity
increase is (30.1 PDs - 10 PDs)/(24.3 PDs - 10 PDs) = 1.406 or a 40.6 % increase in experimental replicative capacity
c Value determined for the growth during the first 30 days
d Probability that mean value is similar to mean value for normal cells: two-tailed t test. In these tests untreated syndrome cells are
compared to untreated normal cells, and SB203580-treated syndrome cells are compared to SB203580-treated normal cells
e Probability that value is within the distribution of normal cells: z-test
f Mean includes data for three other RTS strains, see (Davis et al. 2012) for actual data
g See (Davis and Kipling 2009) for actual data
h See (Davis et al. 2005) for actual data
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morphology, although many of these enlarged cells
do not have F-actin stress fibres (Fig. 2g) and their
morphology was not affected by treatment with
SB203580 (not shown). The morphology of the two
CSB strains differs; CSB(GM10903) has up to 15 %
of cells with an enlarged morphology with F-actin
Fig. 2 Observation of cellular morphology and F-actin stress
fibres in progeroid and genomic instability syndrome fibro-
blasts. Cells were fixed and stained with phalloidin-FITC. For
each panel, the cell type and PD values are given. For a and b a
suffix.c are control cells and a suffix.sb are cells treated with
SB203580: for the other syndromes the effects of SB203580 are
not shown as the effects are small. For syndromes where the
cellular morphology differs little from normal cells only
representative strains are shown. Bars are 100 lm
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stress fibres that were ameliorated with SB203580
(not shown), whereas CSB(GM10905) (Fig. 2h) more
closely resembles NDFs. The morphology of cells
from BS varies between strains, with BS(GM02520)
(Fig. 2i) closely resembling NDFs, whereas
BS(GM02548) (Fig. 2j) and BS(GM02932) (not
shown) have up to 15 % of the cells with an enlarged
morphology with F-actin stress fibres. In the latter two
BS strains treatment with SB203580 results in cultures
with fewer cells with an enlarged morphology (not
shown). A similar pattern is seen in two of the HGPS
strains, with GM11498(HGPS) resembling NDFs (not
shown) and HGPS(AG01972) (Fig. 2k) somewhat
resembling the BS(GM02548) strain with SB203580
having a similar effect (not shown). In the third HGPS
strain [HGPS(AG10677)] the majority of cells are
enlarged with extensive F-actin stress fibres (Fig. 2l)
and SB203580 has little effect on this (not shown).
HGPS(AG10677) cells have a very short replicative
capacity (3.8 PDs, Table 1) and were therefore very
close to replicative senescence when analysed; it has
been shown that senescent cells have an enlarged
morphology that is not affected by SB203580 (Davis
et al. 2005).
Group 3 strains are represented by the single DKC
strain, DKC(GM01774). The cultures of this strain
consisted almost exclusively of enlarged cells with
extensive F-actin stress fibres (Fig. 2m) that were not
affected by SB203580 treatment. Again these cells
were close to replicative senescence by the time of
analysis. For the second strain DKC strain (AG04645)
insufficient cells were obtained for any analysis.
Although we have highlighted the differences,
overall our data reveal only small differences in the
fibroblast morphologies from the various syndromes
and significant inter-strain similarities, particularly
when compared to the reference WS strain (Fig. 2a).
This may not be too surprising as the protein defects
present in the various strains within each syndrome are
very similar despite the different genetic lesions (see
Supplementary Tables 1 and 2). The exception is
HGPS where two strains result from the expression of
Table 2 Summation of cellular morphologies and activation levels of p38 and HSP27
Cell strain % Enlarged cells controla % Enlarged cells SB203580a p38-activationb p-HSP27b
Normal
N(AG16409) \5 \5 ± ?
Group 1 progeroid strain
NBS(RO202) \ \5 – ?
NBS(RO242) \5 \5 – ?
RTS(GM05013) \5 \5 ± ?
SS(GM09812) \5 \5 ± ?
Group 2 progeroid strains
BS(GM02520) \5 \5 ???? ?
BS(GM02932) \15 \10 ± ??
BS(GM02548) \15 \10 ± ??
CSA(GM01856) \20 \20 ?? ????
CSB(GM10903) \15 \5 ? ???
CSB(GM10905) \5 \5 – ??
HGPS(GM11498) \5 \5 – ?
HGPS(GM01972) \15 \10 – ?
HGPS(GM10677) [80 [80 nd nd
Group 3 progeroid strains
DKC(GM01774) [90 [90 nd nd
a The proportion of enlarged cells is estimated from three fields within dish each containing[30 cells for control cells or SB203580
treated cells. Enlargement is a subjective measurement and is not quantitatively measured
b Based upon Fig. 3: -, absent; ±, barely detected or absent; ?, detectable; ??, moderate, ???, strong; ????, very high; nd not
determined, all values are arbitrary based upon comparison between samples
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progerin, and the other, HGPS(AG10677), is due to a
mis-sense lamin A/C protein (Supplementary
Table 1). Whilst it is possible that the differences
seen in this latter strain result from the different
proteins, it appears more likely that the differences
result from the observation that HGPS(AG10677) was
close to senescence when the study began.
Characterisation of stress kinase effector pathways
To assess the activation status of p38, proteins were
extracted from young fibroblasts from each syndrome
[with the exception of HGPS(AG10677) and the two
DKC strains, where there were insufficient cells for
protein analysis] and immunoblots were probed with
antibodies for p38 and its activating phosphorylation.
As a positive control anisomycin-treated HCA2 nor-
mal fibroblasts were used (Fig. 3). These data are
summarised in Table 2.
Very low levels of phosphorylated p38 are found in
N(AG16409), RTS(AG05013), SS(GM09812),
BS(GM02548), BS(GM02932), HGPS(AG11498),
HGPS(AG01972), NBS(RO202), NBS(RO242) and
CSB(GM10905). Moderate levels are seen in the
CSB(GM10903) and CSA(GM01856) strains. A high
level of activated p38 is seen in BS(GM02520),
despite low levels of phosphorylated HSP27 (Fig. 3).
The p38 target MK2 phosphorylates HSP27 on
serines 78 and 82 (Huot et al. 1997). HSP27
phosphorylation is also related to the production of
F-actin stress fibres. Low levels of phosphorylated
HSP27 (p-HSP27) were observed in N(AG16409),
RTS(AG05013), SS(GM09812), BS(GM02520),
HGPS(AG11498), HGPS(AG01972) and the two
NBS strains (Fig. 3). This is in agreement with the
lack of enlarged cellular morphology and F-actin
stress fibres seen in most of these strains.
BS(GM02932) and BS(GM02548) show low to mod-
erate levels of p-HSP27 (Fig. 3) and moderate levels
of F-actin fibres compared to BS(GM02520).
CSB(GM10903) has moderate levels of p-HSP27
and CSB(GM10905) has low p-HSP27 levels. The
CSA(GM01856) strain has moderate to high p-HSP27
levels. In general, the level of p-HSP27 in the cell
strains corresponds with the observation of F-actin
stress fibres and corresponds to the activation status of
p38, with the exception of BS(GM02520) where a
high level of activated p38 does not produce a high
level of p-HSP27 or F-actin stress fibres (Table 2).
hTERT immortalisation of fibroblasts
Fibroblast strains from BS, SS, NBS, CSA, CSB,
HGPS and the normal AG16409 (Table 3) were
transduced with an amphotropic retrovirus expressing
the catalytic subunit of telomerase, hTERT (see
‘‘Materials and Methods’’). In each case, the resulting
puromycin-resistant populations of cells were now
Fig. 3 Immunoblot analysis of stress signalling proteins.
Protein lysates were prepared from primary cells and from
hTERT-immortalized HCA2 cells. Expression levels were
compared for phosphorylated p38 (p-p38), p38, phosphorylated
HSP27 (p-HSP27) and HSP27. HCA2tert cells and HCA2tert
cells treated with anisomycin were used as negative and positive
controls respectively for antibody efficacy (shown in a). Three
sets of immunoblots were done and are shown as a, b, and c, for
each immunoblot HCA2 cells were used as an internal standard
(note that the black lines in b and c indicate that the single lanes
have been cut and pasted from the same gels as the rest of the
samples for each panel, however, the images have been handled
in the same manner otherwise). Protein levels were normalised
with respect to total p38
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telomerase positive as judged by the TRAP assay
(Supplementary Figure 2) with the exception of
NBS(RO242) for which a TRAP positive has not been
possible to obtain. The replicative capacity of each
strain was recorded. In every case telomerase con-
ferred an extension of cellular replicative capacity
beyond senescence, and all telomerase-transduced
cells continue to proliferate at the time of writing.
As an example of normal cells, N(AG16409)tert
cells proliferated more than 46 PDs beyond senes-
cence and are still proliferating (Table 3). Many
different normal fibroblast strains have been immorta-
lised since this was first achieved (Bodnar et al. 1998).
Fibroblasts from several of the syndromes used in
this work have been immortalised previously, albeit
using different strains. For HGPS and BS previous
telomerase-reconstitution experiments have mostly
used strains with a replicative capacity [35 PDs
(Ouellette et al. 2000; Wallis et al. 2004), although the
low replicative capacity strain HGPS(AG01972) has
also been successfully immortalised with telomerase
(Kudlow et al. 2008). To extend these studies we
introduced hTERT into HGPS(AG11498) and
BS(GM02548), both of which are low replicative
capacity strains. Both HGPS(AG11498)tert and
BS(GM02548)tert cells continued proliferation beyond
senescence (Table 3). Thus, hTERT expression can
successfully immortalise primary HGPS and BS
strains irrespective of replicative capability.
The remaining progeroid and genomic instability
syndromes used in this work have not previously been
immortalised using hTERT. The CSA(GM01856)tert,
CSB(GM10903)tert NBS(RO242)tert, SS(GM09812)tert
and cells have all managed at least double the
replicative capacity of uninfected controls and are still
proliferating (Table 3).
The morphologies and stress fibre phenotypes of
TERT-transduced fibroblasts from these syndromes
were essentially the same as seen for the correspond-
ing (uninfected) primary cells for each strain. The
majority of the cells were small with few F-actin stress
fibres visible (not shown). The level of p38 activity (as
judged by p-p38) in each TERT-expressing line was
similar to that seen for the corresponding primary
fibroblasts. That is, if p38 is activated in the primaries
it is also activated in the TERT-expressing samples;
the exception being CSB(GM10903)tert where p38
activity seems to have been suppressed (Fig. 4). These
data suggest that telomerase-mediated immortalisa-
tion of these cell strains has not significantly perturbed
this aspect of the phenotype.
Discussion
Progeroid syndromes are human genetic disorders that
show many, but not all, of the clinical characteristics
of normal ageing (Martin et al. 1999; Hofer et al. 2005;
Kudlow et al. 2008). They are widely used as model
systems to study normal human ageing processes
because, in those aspects where premature ageing
occurs, the process and pathology are remarkably
similar to that seen in normally aged individuals
(Martin et al. 1999). In several of these syndromes,
notably WS, HGPS and AT, premature in vivo ageing
is associated with premature cellular ageing in vitro
Table 3 Growth parameters of progeroid fibroblasts infected with hTERT
Strain PD at infectiona PD of controlb PDs since infectionc TRAP Proliferatingd
N(AG16409) 4 53 99 ? Y
HGPS(AG11498) 10 24 48 ? Y
BS(GM02548) 1 24 98 ? Y
CSA(GM01856) 1 22 101 ? Y
CSB(GM10903) 45 53 38 ? Y
SS(GM09812) 7 32 60 ? Y
NBS(RO242) 53 54 57 - Y
a Replicative age of the culture when infection with hTERT retrovirus took place
b Replicative capacity of uninfected control cultures
c Number of PDs the terted strains had achieved post infection
d Culture is still proliferating at time of manuscript submission
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(Tollefsbol and Cohen 1984; Tchirkov and Lansdorp
2003; Bridger and Kill 2004). In addition, the
premature senescence seen in WS fibroblasts is
prevented using inhibitors of the stress-associated
p38 MAPK (Davis et al. 2005).
Based upon these studies it has been postulated that
premature cellular senescence may underlie many of
the ageing features of these syndromes (Ostler et al.
2002; Faragher et al. 2009). This in turn raises the
question, is shortened cellular replicative capacity a
general characteristic of progeroid syndromes? In this
study we have therefore determined the growth
characteristics and replicative capability of fibroblasts
from several progeroid syndromes and investigated
the role, if any, played by p38 MAP kinase.
The HGPS strains used in this work have a reduced
replicative capacity that is only slightly extended by
SB203580 treatment, but they do not have an ‘‘aged’’
morphology [with the exception of HGPS(AG10677),
which was close to replicative senescence at the start
of this work] and no activated p38. HGPS individuals
have a high rate of ageing and a much reduced
lifespan, and the syndrome is associated with inflam-
matory conditions such as atherosclerosis and osteo-
porosis. Thus, the HGPS cells used in this study have a
reduced replicative capacity, but one that is not
corrected by SB203580.
Cockayne Syndrome has two variants (CSA and
CSB), and it is clear from this work that CSB
fibroblasts do not have an obvious replicative capacity
defect, whereas CSA fibroblasts may do so (Thompson
and Holliday 1983). Both CSA and CSB(GM10903)
fibroblasts show moderate levels of cells with a
stressed morphology and activated p38; however,
SB203580 does not significantly extend the prolifer-
ative capacity of CS fibroblasts beyond that seen in
normals. In addition, SB203580 does not ameliorate
the enlarged morphology seen in the CSA fibroblasts,
although it does so in CSB fibroblasts (Table 2). It is
possible that the enlarged CSA cells have undergone
senescence in a p38-independent fashion, since it has
been shown that SB203580 has no effect of the
morphology of cells that have undergone telomere-
dependent senescence (Davis et al. 2005). The pres-
ence of phosphorylated p38 and HSP27 support this,
because both are activated upon telomere-dependent
replicative senescence (Iwasa et al. 2003; Davis et al.
2005). With CSB(GM10903) cells, the reduction in
the level of cells with an altered cellular morphology
using SB203580, and the observation of activated p38
and phosphorylated HSP27, suggests the presence of a
low level of SIPS. CS individuals have characteristic
facies, thin hair, cachexia, retinal degeneration, hear-
ing loss, neurodegeneration (cerebellar ataxia), and
cataracts (Kraemer et al. 2007). Their clinical course
typifies premature ageing and usually results in early
death, with CSA individuals having a shortened
lifespan (death occurring in the second or third
decade), and CSB individuals dying in the first decade
(Rapin et al. 2000).
BS fibroblasts have a replicative capacity towards
the lower end of the normal range (Thompson and
Holliday 1983; Ouellette et al. 2000), but do not show
an aged morphology (although small numbers of
enlarged cells are present in two strains), and p38 is
only activated in a single strain. BS individuals have a
Fig. 4 Assessment of stress p38 activity in TERT-transduced lines. Immunoblot for phosphorylated p38 (p-p38) and p38
[N(AG16409)tert cells ± anisomycin treatment were used as controls]
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moderately reduced lifespan (Hofer et al. 2005);
however, although classified as a progeroid syndrome,
there is little evidence of a premature ageing defect
apart from a high incidence of type II diabetes in
young BS individuals, and an elevated cancer
incidence.
RTS Syndrome fibroblasts do not show a replicative
defect and little by way of an aged morphology, and
RTS individuals have a normal lifespan (Hofer et al.
2005). However, RTS individuals do show moderate
ageing characteristics, including alopecia, gray hair,
cataracts, and poikiloderma. p38 is not activated in the
one RTS fibroblast strain used in this study.
With NBS, the two strains of cells used here have
no replicative defect, no aged-cell morphology, and no
activated p38. In addition, p38 inhibition has only a
small effect on fibroblast growth. The progeroid
features described for NBS, such as sparse hair and
distinctive ‘bird-like’ facies, do increase with age, but
are relatively mild and there are few inflammatory
features (Seemanova et al. 1985). However, the data
on NBS are potentially confounded by many individ-
uals dying at a young age as a result of cancer.
Fibroblasts from Seckel Syndrome do not have a
reduced replicative capacity and no p38 activation. SS
individuals show moderate ageing with few inflam-
matory features (O’Driscoll et al. 2004), although
accelerated ageing is clearly present in the SS mouse
model (Murga et al. 2009).
The X-linked DKC fibroblasts used in this study
are known to have a shortened replicative capacity but
this is due to deficiencies in telomere maintenance
(Wong and Collins 2006). Whether there is an additional
component due to stress-induced senescence is not clear
from our study for technical reasons, there being
insufficient DKC cells for detailed analysis. The ageing
characteristics in DKC are many, such as alopecia, gray
hair, osteoporosis and abnormal skin pigmentation
(Dokal 2000), but resemble those seen in telomerase
deficient mice (Rudolph et al. 1999) and thus may result
from telomere dysfunction-induced cellular senescence.
Thus, although fibroblasts from several of the
progeroid syndromes show premature cellular senes-
cence, there appears to be no clear relationship
between replicative cellular capacity of the cell strains
used and the presence of premature ageing features.
However, it may be that the presence of accelerated
cellular senescence correlates with the severity of the
ageing phenotype, e.g., in WS, HGPS, and DKC and
AT, the ageing features are marked and the lifespan of
individuals is reduced. However, with RTS and CS the
ageing features are also marked, but fibroblasts have a
normal replicative capacity. Alternatively, tissue
specificity may play a role, since dermal fibroblasts
from WS, HGPS, DKC and AT all show premature
senescence, and a notable feature of these particular
progeroid syndromes is skin ageing. However, this
observed lack of accelerated ageing of fibroblasts (or
SIPS) in no way suggests that features of the ageing
seen in progeroid syndromes are not due to replicative
cellular senescence, or the presence of senescent cells.
In addition, with the exception of WS, there appears
to be no role for the stress kinase p38 in the premature
senescence seen in fibroblasts from the progeroid
syndromes used in this study. With regards to p38,
there also appears to be no correlation between p38
activation and the presence of inflammatory features.
Thus it would be useful to examine other cell types
from these syndromes, e.g., vascular smooth muscle
cells in HGPS are reported to be depleted from the
large arteries in HGPS individuals (Stehbens et al.
2001), which may be due to accelerated senescence or
apoptosis. Overall, our study demonstrates that accel-
erated fibroblast senescence and p38 activation are
features of some, but not all, genome instability and
progeroid syndromes.
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